Medicare GLP-1 Bridge enrollment passes half a million in two months

Enrollment in Medicare's new $50-a-month GLP-1 program has climbed into the hundreds of thousands within two months of launch. Centers for Medicare & Medicaid Services Administrator Mehmet Oz said Monday that roughly 600,000 Medicare beneficiaries have signed up for the Medicare GLP-1 Bridge since it opened on July 1 ^[1].

A separate White House tally put enrollment at more than 500,000 and claimed $216 million in savings. The two figures were released within days of each other, and the reason for the gap — different cutoff dates, different counting methods, or something else — is not explained in the available reporting ^[1]. Readers should treat both numbers as preliminary agency estimates rather than audited counts.

What the program covers

The Bridge is a temporary CMS demonstration announced in May and launched July 1. It is authorized through December 31, 2027 ^[1]. Under the program, eligible beneficiaries pay a flat $50 monthly copay for covered obesity medications, regardless of income ^[1]. Before the program, out-of-pocket costs for these drugs often exceeded $1,000 a month ^[1].

The covered list is narrow. It includes Wegovy (semaglutide), the KwikPen form of Eli Lilly's Zepbound (tirzepatide), and Foundayo, the oral GLP-1 also known by its molecule name orforglipron ^[1]. Other brands and other device formats are not named in the program description.

Eligibility runs through Medicare Part D. Beneficiaries generally need Part D prescription coverage plus one of these clinical criteria: a body mass index of 35 or higher; a BMI of 30 or higher with certain qualifying health conditions; or a BMI of 27 or higher along with specific cardiovascular disease history or prediabetes ^[1].

Some people are deliberately steered away from the Bridge. Medicare guidance says beneficiaries with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease should seek coverage through their existing Part D plans instead, because those conditions may already qualify for coverage ^[1].

"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," Oz said when the program was announced ^[1]. Chris Klomp, Medicare director and chief counselor at the Department of Health and Human Services, described the demonstration as designed to make access "simpler, more predictable, and more consistent across the Medicare program" ^[1].

How many people could qualify

An estimated 3.8 million Medicare beneficiaries meet the program's criteria, according to KFF. Measured against that figure, the reported enrollment of 500,000 to 600,000 represents a fraction of the potentially eligible population after two months. The provided reporting does not break down how many of those who signed up have actually filled a prescription, how many stayed on treatment, or how the enrollment is split across the three covered drugs ^[1].

Why it matters for patients

The practical effect is a swap of an unpredictable cost for a fixed one. "The biggest thing this program is doing for seniors is turning access to these drugs from a potentially enormous expense into a predictable $50 monthly decision," financial planner Michael Ryan told Newsweek. "Getting 600,000 people enrolled in just two months tells you there was substantial demand" ^[1].

The bigger question is what happens when the demonstration ends. "This isn't permanent coverage," Ryan said. If Medicare later folds comparable coverage into Part D, the Bridge may work as its name suggests. If it does not, "seniors who became accustomed to paying $50 could suddenly face much higher costs or difficult coverage decisions" ^[1].

Kevin Thompson, CEO of 9i Capital Group, raised a second concern: that a large influx of new users could strain supply for people who take these drugs for other conditions ^[1]. He also noted that many patients regain weight after stopping, and that digestive side effects are possible ^[1]. Whether supply problems actually materialize is not established in the available reporting.

What happens next

The Bridge runs through December 31, 2027 ^[1]. CMS is expected to use enrollment, cost and outcomes data from the demonstration to judge whether broader Medicare coverage of obesity drugs should continue or change ^[1]. No decision on what follows the program has been announced.